Top

Published in:

01-03-2013 | HIV Pathogenesis and Treatment (A Landay, Section Editor)

Immunity and Hepatitis C: A Review

Authors: Rebecca R. Terilli, Andrea L. Cox

Published in: Current HIV/AIDS Reports | Issue 1/2013

Abstract

Hepatitis C virus (HCV) is a major cause of chronic hepatitis and hepatocellular carcinoma worldwide. Due to shared transmission routes, the prevalence of HCV is especially high among individuals infected with HIV. HIV uninfected individuals spontaneously clear HCV approximately 30 % of the time, while the rate of control in HIV infected individuals who subsequently acquire HCV is substantially lower. In addition, complications of HCV are more frequent in those with HIV infection, making liver disease the leading cause of non-AIDS-related death in HIV infected individuals. This review summarizes recent advances in understanding the role of the innate and adaptive immune responses to HCV in those with and without HIV. Further defining the interaction between hepatitis C and the host immune system will potentially reveal insights into HCV pathogenesis and the host’s ability to prevent persistent infection, as well as direct the development of vaccines.

World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997; 341–8.

Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.PubMedCrossRef

Li K, Lemon S. Innate immune responses in hepatitis C virus infection. Semin Immunopathol. 2012; Aug 7 [Epub ahead of print].

Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745–54.PubMedCrossRef

Sherman KE, Rouster SD, Chung R, et al. Hepatitis C prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–7.PubMedCrossRef

The Centers for Disease Control. HIV and Viral Hepatitis. Available at http://www.cdc.gov/hiv/resources/factsheets/hepatitis.htm. Accessed October 2012.

Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32(3):492–7.PubMedCrossRef

Gale Jr M, Foy EM. Evasion of intracellular host defense by hepatitis C virus. Nature. 2005;436(7053):939–45.PubMedCrossRef

Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA. 2005;102(8):2992–7.PubMedCrossRef

10.

Balagopal A, Thomas DL, Thio CL, et al. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2012;139(6):1865–76.CrossRef

11.

• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. Early in a series of landmark papers demonstrating that patients infected with HCV who had one of two variants in the IL28B locus (rs12979860 CC or rs8099917 TT) were significantly more likely to respond to PEG-IFN-α /ribavirin therapy and to spontaneously resolve acute HCV infection than patients with other IL28B variants. Hundreds of subsequent studies have examined the role of IL28B polymorphisms in HCV infection and treatment and a test for the IL28B variants is in use to guide clinical decision making.PubMedCrossRef

12.

Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.PubMedCrossRef

13.

Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.PubMedCrossRef

14.

Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338–45.PubMedCrossRef

15.

Lanford RE, Guerra B, Bigger CB, et al. Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology. 2007;46(4):999–1008.PubMedCrossRef

16.

McGilvray I, Feld JJ, Chen L, et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology. 2012;142(4):1122–31.PubMedCrossRef

17.

Naggie S, Osinusi A, Katsounas A, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response. Hepatology. 2012;56(2):444–54.PubMedCrossRef

18.

Thomas E, Gonzalez VD, Qisheng L, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2011;142:978–88.CrossRef

19.

Park H, Serti E, Eke O, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology. 2012. doi:10.1002/hep.25897.

20.

Ahlenstiel G, Titerence RH, Koh C, et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology. 2010;138(1):325–35.PubMedCrossRef

21.

Amadei B, Urbani S, Cazaly A, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology. 2010;138:1536–45.PubMedCrossRef

22.

Zeromski J, Mozer-Lisewska I, Kaczmarek M, et al. NK cells prevalence, subsets and function in viral hepatitis C. Arch Immunol Ther Exp (Warsz). 2011;59:449–55.CrossRef

23.

Mengshol JA, Golden-Mason L, Arikawa T, et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One. 2010;5(3):e9504.PubMedCrossRef

24.

Chattergoon M, Levine JS, Latanich R, et al. High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis. 2011;204(11):1730–40.PubMedCrossRef

25.

An P, Thio CL, Kirk G, et al. Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance. J Infect Dis. 2008;198(8):1159–65.PubMedCrossRef

26.

Mosbruger TL, Duggal P, Goedert JJ, et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis. 2010;201(9):1371–80.PubMedCrossRef

27.

• Takahashi K, Shinichi A, Wieland S, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. PNAS. 2012;107(16):7431–6. The HCV NS3/4A protease blocks the innate host response in infected hepatocyte cell lines in vitro, but HCV induces a strong type 1 interferon response in the infected liver so the source of that interferon was unclear. This paper demonstrated that HCV-infected cells induce an interferon response in pDCs by a mechanism that requires active viral replication, direct cell-cell contact, and Toll-like receptor 7 signaling. These findings highlight a potential source for interferon in acute HCV infection that could result in HCV inhibition in vivo.CrossRef

28.

Zhang S, et al. CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of HCV-infected cells and induction of IFNα. Hepatology. 2012. 10.1002/hep.25827.

29.

Perrella A, Atripaldi L, Bellopede P, et al. Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms. World J Gastroenterol. 2006;12(7):1105–9.PubMed

30.

Hancharou AY, Titov LP, DuBuske LM. Altered phenotype and function of monocyte-derived dendritic cells in acute hepatitis C and chronic hepatitis C. J Allergy Clin Immunol. 2009;123(2):S221.CrossRef

31.

Ulsenheimer A, Gerlach JT, Jung MC, et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology. 2005;41(3):643–51.PubMedCrossRef

32.

Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood. 2001;97(10):3171–6.PubMedCrossRef

33.

Barnes E, Salio M, Cerundolo V, et al. Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat. 2008;15(3):219–28.PubMedCrossRef

34.

• Kim A, Chung R. Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology. 2009;137(3):795–814. An excellent review of the mechanisms used by HIV and HCV to evade immune system control, epidemiologic associations that render coinfection common, and the pathogenesis of accelerated liver disease in patients with HIV-1/HCV coinfection.PubMedCrossRef

35.

Lambotin M, Barth H, Moog C, et al. Challenges for HCV vaccine development in HIV-HCV coinfection. Expert Rev Vaccines. 2012;11(7):791–804.PubMedCrossRef

36.

Parczewski M, Bander D, Leszczyszyn-Pynka M, et al. IL28B CC genotype is associated with higher all-cause mortality in hiv-infected patients. AIDS Res Hum Retroviruses. 2012; Jun 4 [Epub ahead of print].

37.

Hou W, Wang X, Ye L, et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol. 2009;83(8):3834–42.PubMedCrossRef

38.

Liu MQ, Zhou DJ, Wang X, et al. IFN-λ3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS One. 2012;7(4):e35902.PubMedCrossRef

39.

Lambotin M, Raghuraman S, Stoll-Keller F, et al. A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol. 2010;8(5):350–60.PubMedCrossRef

40.

Iannello A, Debbeche O, Samarani S, et al. Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination. J Leukoc Biol. 2008;84:27–49.PubMedCrossRef

41.

Chen M, Sallberg M, Sonnerborg A, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology. 1999;116(1):135–43.PubMedCrossRef

42.

Netski DM, Mosburger T, Depla E, et al. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis. 2005;41(5):667–75.PubMedCrossRef

43.

Cox AL, Mosbruger T, Lauer GM, et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology. 2005;42(1):104–12.PubMedCrossRef

44.

Christie JM, Healey CJ, Watson J, et al. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol. 1997;110(1):4–8.PubMedCrossRef

45.

Logvinoff C, Major ME, Oldach D, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. PNAS. 2004;101(27):10149–54.PubMedCrossRef

46.

Dowd KA, Netski DM, Wang XH, et al. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology. 2009;136(7):2377–86.PubMedCrossRef

47.

Raghuraman S, Park H, Osburn W, et al. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis. 2012;205:763–71.PubMedCrossRef

48.

Fournillier A, Freida D, Defrance T, et al. Analysis of B-lymphocyte differentiation in patients infected with hepatitis C virus. J Med Virol. 2004;72(4):566–74.PubMedCrossRef

49.

Oliviero B, Cerino A, Varchetta S, et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J Hepatol. 2011;55(1):53–60.PubMedCrossRef

50.

Racanelli V, Frassanito MA, Leone P, Galiano M, De Re V, Silvestris F, et al. Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules. J Virol. 2006;80:3923–34.PubMedCrossRef

51.

Rosa D, Saletti G, De Gregorio E, et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA. 2005;102:18544–9.PubMedCrossRef

52.

Holz LE, Yoon JC, Raghuraman S, et al. B-cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B-cell apoptosis. Hepatology. 2012. doi:10.1002/hep.25821.

53.

Roughan J, Reardon K, Cogburn K, et al. Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Clin Vaccine Immunol. 2012;19(7):1027–37.PubMedCrossRef

54.

Forghieri F, Luppi M, Barozzi P, et al. Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin Dev Immunol. 2012;2012:1–9.CrossRef

55.

Walker CM. Adaptive immunity to heptitis C virus, advances in virus research. In: Maramorosch K, Shatkin AJ, Murphy FA, editors. New York: Academic; 2010:(78)43–86.

56.

Neumann-Haefelin C, Thimme R. Success and failure of virus-specific T cell responses in hepatitis C virus infection. Dig Dis. 2011;29(4):416–22.PubMedCrossRef

57.

Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut. 2012;61:1226–34.PubMedCrossRef

58.

Shin EC, Park SH, Demino M, et al. Delayed induction, not impaired recruitment of specific CD8(+) T cells, causes the late onset of acute hepatitis C. Gastroenterology. 2011;141(2):686–95.PubMedCrossRef

59.

Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003;197(12):1645–55.PubMedCrossRef

60.

Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302(5645):659–62.PubMedCrossRef

61.

Moroshima C, Di Bisceglie AM, Rothman AL, et al. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat. 2012;19(6):404–13.CrossRef

62.

Cox AL, Mosbruger T, Mao Q, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med. 2005;201(11):1741–52.PubMedCrossRef

63.

Dazert E, Neumann-Haefelin C, Bressanelli S, et al. Loss of viral fitness and cross-recognition by CD8 + T cells limit HCV escape from a protective HLA-B27—restricted human immune response. J Clin Invest. 2009;119:376–86.PubMed

64.

Kunholm MH, Kavacs A, Gao X, et al. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology. 2010;51(5):1514–22.CrossRef

65.

Kim AY, Kuntzen T, Timm J, et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology. 2011;140(2):686–96.PubMedCrossRef

66.

zur Schulze Wiesch J, Ciuffreda D, Lewis-Ximenez L, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med. 2012;209(1):61–75.CrossRef

67.

Rutebemberwa A, Ray SC, Astemborski J, et al. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronice infection. J Immunol. 2008;181:8215–25.PubMed

68.

Bengsch B, Seigel B, Ruhl M, et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathogens. 2010;6(6):e1000947.PubMedCrossRef

69.

McMahan RH, Golden-Mason L, Nishimure MI, et al. Tim-3 expression on PD-1 + HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest. 2010;120(12):4546–57.PubMedCrossRef

70.

Netski D, Mosbruger TJ, Astemborski J, et al. CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J Infect Dis. 2007;195(6):857–63.PubMedCrossRef

71.

Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012;55(6):1652–61.PubMedCrossRef

72.

• Osburn W, Fisher B, Dowd K, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138(1):315–24. This paper demonstrated that HCV reinfection is associated with a reduction in the magnitude and duration of viremia versus the initial infection with associated broadening of the cellular immune response and generation of cross-reactive humoral responses. These findings are consistent with the development of adaptive immune responses that protect against persistent disease in the absence of sterilizing immunity. The fact that protective immunity is possible highlights the plausibility of a preventive vaccine since sterilizing immunity may not be required.PubMedCrossRef

73.

Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet. 2002;359:1478–83.PubMedCrossRef

74.

Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult drug users: a prospective study of incident infection, resolution and reinfection. J Infect Dis. 2009;200:1216–26.PubMedCrossRef

75.

Ramalingam RK, Meyer-Olson D, Shoukry NH, et al. Kinetic analysis by real-time PCR of hepatitis C virus (HCV)-specific T cells in peripheral blood and liver after challenge with HCV. J Virol. 2008;82(21):10487–92.PubMedCrossRef

76.

Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12(2):190–7.PubMedCrossRef

77.

• Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4(115):115ra1. This paper describes the use of non-human primate adenoviral vector systems encoding HCV antigens to generate robust T cell responses to HCV. These novel vectors are highly immunogenic, appear safe, and antibodies directed against human adenoviruses are minimally cross reactive against them. This vaccine platform forms the foundation of the only prophylactic HCV vaccine trial performed to date in at-risk individuals.PubMedCrossRef

78.

Meunier JC, Gottwein JM, Houghton M, et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis. 2011;204(8):1186–90.PubMedCrossRef

79.

Drane D, Maraskovsky E, Gibson R, et al. Priming of CD4 + and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccines. 2009;5(3):151–7.CrossRef

80.

Garrone P, Fluckiger AC, Mangeot PE, et al. A prime–boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med. 2011;3(94):94ra71.PubMedCrossRef

81.

Lin Y, Kwon T, Polo J, et al. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol. 2008;82(15):7492–503.PubMedCrossRef

Title: Immunity and Hepatitis C: A Review
Authors: Rebecca R. Terilli
Andrea L. Cox
Publication date: 01-03-2013
Publisher: Current Science Inc.
Published in: Current HIV/AIDS Reports / Issue 1/2013
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-012-0146-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Attacking the HIV Reservoir from the Immune and Viral Perspective

Understanding and Controlling Chronic Immune Activation in the HIV-Infected Patients Suppressed on Combination Antiretroviral Therapy

Intersecting Epidemics Among Pregnant Women: Alcohol Use, Interpersonal Violence, and HIV Infection in South Africa

State of Condom Use in HIV Prevention Science and Practice

Revising the Role of Myeloid cells in HIV Pathogenesis

HIV: So Near and Yet So Far

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials